Literature DB >> 21728005

Renal amyloidosis caused by apolipoprotein A-II without a genetic mutation in the coding sequence.

Ryuji Morizane1, Toshiaki Monkawa2, Konosuke Konishi2, Akinori Hashiguchi3, Mitsuharu Ueda4, Yukio Ando4, Hirobumi Tokuyama2, Koichi Hayashi2, Matsuhiko Hayashi5, Hiroshi Itoh2.   

Abstract

Although the majority of renal amyloidosis is caused by either acquired monoclonal immunoglobulin light-chain amyloidosis or reactive systemic amyloid A, some cases are caused by hereditary amyloidosis. Apolipoprotein A-II (apoAII) amyloidosis is a rare form of hereditary amyloidosis and cannot be diagnosed by a routine examination. Thus, the prevalence and etiology of apoAII amyloidosis are uncertain. In humans, a genetic mutation in the stop codon of apoAII is considered to be a cause of amyloid fibril formation. We report on a 68-year-old man who presented with proteinuria by apoAII amyloidosis without family history. His proteinuria gradually increased to 6 g/day within 1 year. A renal biopsy showed amyloid deposition in the glomeruli, however, acquired monoclonal immunoglobulin light-chain amyloidosis and reactive systemic amyloid A were ruled out. Immunohistochemistry revealed apoAII deposition in the glomeruli, but DNA sequencing did not identify any genetic mutation in the coding sequence of apoAII. Here, we report a case of apoAII amyloidosis without a genetic mutation in the coding sequence and discuss the etiology of apoAII amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21728005     DOI: 10.1007/s10157-011-0483-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  14 in total

1.  Transmission of mouse senile amyloidosis.

Authors:  Y Xing; A Nakamura; T Chiba; K Kogishi; T Matsushita; F Li; Z Guo; M Hosokawa; M Mori; K Higuchi
Journal:  Lab Invest       Date:  2001-04       Impact factor: 5.662

2.  A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene.

Authors:  M D Benson; J J Liepnieks; M Yazaki; T Yamashita; K Hamidi Asl; B Guenther; B Kluve-Beckerman
Journal:  Genomics       Date:  2001-03-15       Impact factor: 5.736

3.  Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis.

Authors:  K Higuchi; K Kitagawa; H Naiki; K Hanada; M Hosokawa; T Takeda
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

4.  Transmission of amyloidosis in offspring of mice with AApoAII amyloidosis.

Authors:  Tatsumi Korenaga; Jingmin Yan; Jinko Sawashita; Takatoshi Matsushita; Hironobu Naiki; Masanori Hosokawa; Masayuki Mori; Keiichi Higuchi; Xiaoying Fu
Journal:  Am J Pathol       Date:  2006-03       Impact factor: 4.307

5.  Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series.

Authors:  Charles L Murphy; Shuching Wang; Daniel Kestler; Christopher Larsen; Don Benson; Deborah T Weiss; Alan Solomon
Journal:  Am J Kidney Dis       Date:  2010-10-16       Impact factor: 8.860

6.  Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene.

Authors:  M Yazaki; J J Liepnieks; T Yamashita; B Guenther; M Skinner; M D Benson
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

7.  Mouse senile amyloid fibrils deposited in skeletal muscle exhibit amyloidosis-enhancing activity.

Authors:  Jinze Qian; Jingmin Yan; Fengxia Ge; Beiru Zhang; Xiaoying Fu; Hiroshi Tomozawa; Jinko Sawashita; Masayuki Mori; Keiichi Higuchi
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

8.  Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg.

Authors:  Masahide Yazaki; Juris J Liepnieks; Mark S Barats; Arthur H Cohen; Merrill D Benson
Journal:  Kidney Int       Date:  2003-07       Impact factor: 10.612

9.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.

Authors:  Helen J Lachmann; David R Booth; Susanne E Booth; Alison Bybee; Janet A Gilbertson; Julian D Gillmore; Mark B Pepys; Philip N Hawkins
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

10.  Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations.

Authors:  Per Westermark; Joakim Bergström; Alan Solomon; Charles Murphy; Knut Sletten
Journal:  Amyloid       Date:  2003-08       Impact factor: 7.141

View more
  5 in total

1.  Apolipoprotein AII levels are associated with the UP/UCr levels in idiopathic steroid-sensitive nephrotic syndrome.

Authors:  Takahiro Kanai; Takanori Yamagata; Takane Ito; Jun Odaka; Takashi Saito; Jun Aoyagi; Mariko Y Momoi
Journal:  Clin Exp Nephrol       Date:  2014-03-15       Impact factor: 2.801

2.  Triglyceride increase in the core of high-density lipoproteins augments apolipoprotein dissociation from the surface: Potential implications for treatment of apolipoprotein deposition diseases.

Authors:  Shobini Jayaraman; Jose Luis Sánchez-Quesada; Olga Gursky
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-10-18       Impact factor: 5.187

Review 3.  The genetics of cardiac amyloidosis.

Authors:  Scott Arno; Jennifer Cowger
Journal:  Heart Fail Rev       Date:  2021-09-13       Impact factor: 4.654

4.  Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant.

Authors:  Tatiana Prokaeva; Harun Akar; Brian Spencer; Andrea Havasi; Haili Cui; Carl J O'Hara; Olga Gursky; John Leszyk; Martin Steffen; Sabrina Browning; Allison Rosenberg; Lawreen H Connors
Journal:  Kidney Int Rep       Date:  2017-07-29

Review 5.  Renal amyloidosis: a new time for a complete diagnosis.

Authors:  V A Feitosa; P D M M Neves; L B Jorge; I L Noronha; L F Onuchic
Journal:  Braz J Med Biol Res       Date:  2022-10-03       Impact factor: 2.904

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.